Skip to content

13F-HR/A filed by Sarissa Capital Management LP

Sarissa Capital Management LP filed this 13F-HR/A for the quarter ended 2017-12-31, filed 2018-02-23, with 11 holding rows worth $390,650,000.

Accession
0001140361-18-009863
Filed
2018-02-23
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2017

A holdings report, amendment of type restatement, 11 entries on the cover page, a total value of $390,650,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $390,650,000 with VALUE read as thousands by filing date, 13F file number 028-15935. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
BIOGEN INC COM09062X103Stock413,858$131,842,000thousands by filing date
BIOVERATIV INC09075E100COM1,165,000$62,816,000thousands by filing date
MEDICINES CO584688105COM1,922,000$52,547,000thousands by filing date
INNOVIVA INC45781M101COM3,660,705$51,945,000thousands by filing date
ALLERGAN PLCG0177J108SHS257,300$42,089,000thousands by filing date
IRONWOOD PHARMACEUTICALS INC46333X108COMMON STOCK1,650,000$24,733,000thousands by filing date
INTERCEPT PHARMACEUTICALS IN45845P108COM182,300$10,649,000thousands by filing date
ACHILLION PHARMACEUTICALS IN00448Q201COM2,500,000$7,200,000thousands by filing date
NOVELION THERAPEUTICS INC67001K202COM NEW1,025,000$3,198,000thousands by filing date
APRICUS BIOSCIENCES INC03832V307COM NEW1,447,906$2,664,000thousands by filing date
AbbVie,Inc.00287Y109COM10,000$967,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001140361-18-008303 superseded2018-02-14acceptance time not in the bulk data set
13F-HR/A 0001140361-18-009863this filing2018-02-23acceptance time not in the bulk data set